Actively Recruiting
Study of Felzartamab IV Infusions in Adults With Kidney Transplants and Late Isolated Microvascular Inflammation
Led by Biogen · Updated on 2026-07-31
81
Participants Needed
42
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying felzartamab in adults who have received a kidney transplant and later developed microvascular inflammation MVI, a condition causing injury to small blood vessels in the transplanted kidney. Some cases of MVI occur without antibodies and are called isolated MVI, for which there are currently no approved treatments. This research aims to understand how felzartamab affects inflammation in the transplanted kidney and related health aspects. Participants are randomly assigned to receive either felzartamab or a placebo for 24 weeks without knowing which they receive. After this, all participants receive felzartamab openly for another 28 weeks. Treatments are given through intravenous IV infusions at the study site. Kidney biopsies are done at the start, week 24, and week 52 to observe changes in inflammation. Throughout the study, participants will have lab tests and health monitoring, including recording any health problems that may happen. Researchers will measure kidney inflammation, function, immune activity, and overall health over about one year. Safety is closely watched using biopsies, lab results, and adverse event reports to better understand felzartamabs effects.
CONDITIONS
Brief Title
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Research Team
U
US Biogen Clinical Trial Center
G
Global Biogen Clinical Trial Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
